Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Thomson AW et al. | FK 506, cardiac transplantation, and graft-vessel disease. | 1992 | Lancet | pmid:1370563 |
First MR | Transplantation in the nineties. | 1992 | Transplantation | pmid:1370734 |
Naito M et al. | Reversal of multidrug resistance by an immunosuppressive agent FK-506. | 1992 | Cancer Chemother. Pharmacol. | pmid:1370765 |
Kim YI et al. | Stimulation of liver regeneration by pretreatment with azathioprine as well as cyclosporine and FK506. | 1992 | Transplantation | pmid:1373539 |
Carobbi A et al. | Synergism of splenectomy and immunosuppressive drugs in prolongation of cardiac xenograft survival. | 1992 | Transplant. Proc. | pmid:1373543 |
Ueno M et al. | Immunosuppressive effect in combination therapy of cyclosporine A, FK 506, and 15-deoxyspergualin on pancreatic islet xenotransplantation. | 1992 | Transplant. Proc. | pmid:1373546 |
Matsuzaki T et al. | Liver transplantation for diethylnitrosamine-induced hepatocellular carcinoma in rats. | 1992 | Transplant. Proc. | pmid:1373547 |
Wiederrecht G et al. | Isolation of a human cDNA encoding a 25 kDa FK-506 and rapamycin binding protein. | 1992 | Biochem. Biophys. Res. Commun. | pmid:1376117 |
Bernstein L and Daviss SR | Organic anxiety disorder with symptoms of akathisia in a patient treated with the immunosuppressant FK506. | 1992 | Gen Hosp Psychiatry | pmid:1376291 |
Hatfield SM et al. | Rapamycin and FK506 differentially inhibit mast cell cytokine production and cytokine-induced proliferation and act as reciprocal antagonists. | 1992 | J. Pharmacol. Exp. Ther. | pmid:1376361 |
Takaya S et al. | Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. | 1992 | Transplantation | pmid:1279851 |
Partaledis JA et al. | Saccharomyces cerevisiae contains a homolog of human FKBP-13, a membrane-associated FK506/rapamycin binding protein. | 1992 | Yeast | pmid:1279908 |
Ozawa K et al. | An appraisal of pediatric liver transplantation from living relatives. Initial clinical experiences in 20 pediatric liver transplantations from living relatives as donors. | 1992 | Ann. Surg. | pmid:1280074 |
Tocci MJ and Sigal NH | Recent advances in the mechanism of action of cyclosporine and FK506. | 1992 | Curr. Opin. Nephrol. Hypertens. | pmid:1285380 |
Bavandi A et al. | Diet-induced dermatitis response of hairless rats to systemic treatment with cyclosporin A (Sandimmun), cyclosporin H and FK506. | 1992 | Exp. Dermatol. | pmid:1285411 |
High KP and Handschumacher RE | Immunity, microbial pathogenesis, and immunophilins: finding the keys, now where are the locks? | 1992 | Infect Agents Dis | pmid:1285413 |
Akutsu I et al. | [Inhibitory effect of inhaled FK-506 on increased bronchial responsiveness and eosinophil infiltration in the airway mucosa]. | 1992 | Arerugi | pmid:1377905 |
Takada K et al. | Distribution kinetics of FK-506, a novel immunosuppressant, after intravenous administration to rats in comparison with cyclosporin A. | 1992 | Biopharm Drug Dispos | pmid:1379839 |
Kahan BD | Cyclosporin A, FK506, rapamycin: the use of a quantitative analytic tool to discriminate immunosuppressive drug interactions. | 1992 | J. Am. Soc. Nephrol. | pmid:1379841 |
Lauerma AI et al. | Inhibition of contact allergy reactions by topical FK506. | 1992 | Lancet | pmid:1380111 |
Mittrücker HW and Fleischer B | Functional localization of an exocytosis-triggering G-protein in human cytotoxic T lymphocytes. | 1992 | Immunology | pmid:1383135 |
Yasutomi D et al. | Inhibition of programmed cell death by cyclosporin A; preferential blocking of cell death induced by signals via TCR/CD3 complex and its mode of action. | 1992 | Immunology | pmid:1383138 |
Ruff VA et al. | Tissue distribution and cellular localization of hsp56, an FK506-binding protein. Characterization using a highly specific polyclonal antibody. | 1992 | J. Biol. Chem. | pmid:1383222 |
Jordan ML et al. | Initial studies with FK506 in renal transplantation. | 1991 Sep-Oct | Cleve Clin J Med | pmid:1718631 |
Kobayashi M et al. | FK 506 assay past and present--characteristics of FK 506 ELISA. | 1991 | Transplant. Proc. | pmid:1721258 |
Warty VS et al. | Practical aspects of FK 506 analysis (Pittsburgh experience). | 1991 | Transplant. Proc. | pmid:1721259 |
McCauley J et al. | Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation. | 1991 | Transplant. Proc. | pmid:1721290 |
McLachlan G et al. | Growth inhibition of the MOLT-4 human T-leukemia cell line. A comparison of cyclosporine and FK 506. | 1991 | Transplant. Proc. | pmid:1721291 |
Takaori K et al. | Effects of FK 506 on in vivo immunity in comparison to cyclosporine. | 1991 | Transplant. Proc. | pmid:1721322 |
Jordan ML et al. | Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium. | 1991 | Transplant. Proc. | pmid:1721323 |
Paul AA et al. | CMV retinitis and the use of FK 506. | 1991 | Transplant. Proc. | pmid:1721354 |
Keicho N et al. | Effects of an immunosuppressant, FK506, on interleukin 1 alpha production by human macrophages and a macrophage-like cell line, U937. | 1991 | Cell. Immunol. | pmid:1703047 |
Reyes J et al. | Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721355 |
White DJ | FK506: the promise and the paradox. | 1991 | Clin. Exp. Immunol. | pmid:1703053 |
McCauley J et al. | Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721387 |
Hossein-Nia M et al. | Urinary proteins as a marker of drug-induced renal damage following treatment with cyclosporine or FK 506. | 1991 | Transplant. Proc. | pmid:1721388 |
Masaoka T et al. | Phase II study of FK 506 for allogeneic bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721417 |
Markus PM et al. | The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721418 |
Brabletz T et al. | The immunosuppressives FK 506 and cyclosporin A inhibit the generation of protein factors binding to the two purine boxes of the interleukin 2 enhancer. | 1991 | Nucleic Acids Res. | pmid:1707162 |
Iwaki Y et al. | Replacement of donor lymphoid tissue in small-bowel transplants. | 1991 | Lancet | pmid:1707470 |
Abu-Elmagd K et al. | FK 506: a new therapeutic agent for severe recalcitrant psoriasis. | 1991 | Transplant. Proc. | pmid:1721449 |
Nikolaidis NL et al. | Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. | 1991 | Transplant. Proc. | pmid:1721450 |
Markus PM et al. | FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. | 1991 | Surgery | pmid:1713358 |
Farley DE et al. | The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. | 1991 | Transplantation | pmid:1713360 |
Jiang H et al. | Effect of FK-506 on heart allograft survival in the highly sensitized recipient rats as compared with ciclosporin and 15-deoxyspergualin. | 1991 | Eur Surg Res | pmid:1723683 |
Pezze JL and Whiteman K | Transplantation's newest weapon FK 506. | 1991 | Am J Nurs | pmid:1716857 |
Fung JJ et al. | Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. | 1991 | Transplant. Proc. | pmid:1703682 |
Marquis-Omer D et al. | Stabilization of the FK506 binding protein by ligand binding. | 1991 | Biochem. Biophys. Res. Commun. | pmid:1716886 |
Altmeyer A et al. | Unexpected up-regulation of gene expression by cyclosporin A and FK-506 in a T-cell lymphoma: both immunosuppressants augment Ly-6E antigen induction by interferon-gamma in the presence of ionomycin. | 1991 | Int. J. Immunopharmacol. | pmid:1726093 |
Gordon RD et al. | Liver transplantation at the University of Pittsburgh, 1984 to 1990. | 1991 | Clin Transpl | pmid:1726458 |